The 2026 coverage landscape
GLP-1 coverage has expanded significantly but remains inconsistent. About 40–50% of large employer plans now cover Wegovy or Zepbound for obesity. State mandates in California, Colorado, Illinois, Maryland, Massachusetts, New York, Oregon, and Washington require coverage for qualified plans.
| Plan Type | Coverage Rate | Typical Out-of-Pocket |
|---|---|---|
| Large employer (covering) | ~45% of plans | $0–225/mo with savings card |
| Medicare (CVD indication) | Yes since 2024 | $35–150/mo (Part D) |
| Mandate state ACA Gold | Often covered | Varies by plan |
| Medicaid (mandate states) | Covered | $0–nominal copay |
| Medicare (obesity only) | Not covered by law | Full list price or alternatives |
| Small employer | ~25% of plans | Varies widely |
How to appeal a denial
A prior authorization denial is not the end of the road. Studies show that 30–50% of GLP-1 denials are overturned on appeal when properly documented. Key steps:
- Get a Letter of Medical Necessity (LMN) from your provider documenting your BMI, qualifying conditions, and treatment history
- Request a peer-to-peer review — your provider speaks directly with the insurance company's medical reviewer, which significantly improves approval rates
- Use the external appeals process if the internal appeal is denied — independent reviewers overturn decisions in about 40% of cases
- Contact Honest Care — a service that helps patients write and submit insurance appeals, with a free template available
Document everything: Keep records of all communications with your insurer, including dates, representative names, and reference numbers. This documentation is essential for appeals.
FAQ
Call the member services number on the back of your insurance card. Ask specifically: "Does my plan cover semaglutide (brand name Wegovy) or tirzepatide (brand name Zepbound) for obesity or weight management?" Ask for the formulary tier and any prior authorization requirements. You can also check your plan's drug formulary online — look up the plan name + "formulary" or "drug list."
Medicare currently covers Wegovy only for patients with established cardiovascular disease (since 2024). Medicare does not cover GLP-1 medications for obesity alone — a law from the 1990s prohibits Medicare from covering "weight loss drugs." Congressional legislation to change this has been proposed but not passed as of April 2026.